Addressing ART Safety and Tolerability in Transgender Individuals

In this episode, Jill Blumenthal, MD, MAS, and Jennifer Cocohoba, PharmD, share how they manage possible antiretroviral (ARV)-associated toxicities in transgender individuals, including:

• Strategies on how to approach different ARV-related toxicities
• Other factors to consider when assessing possible ARV-related toxicities (eg, weight gain, cardiovascular disease), such as gender-affirming care and nonmedication risk factors (eg, smoking, life stressors)
• Clinically relevant drug–drug interactions related to HIV and gender-affirming care
• Methods to reduce barriers to ART adherence

Faculty: 

Jill Blumenthal, MD, MAS
Associate Professor of Medicine
Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California

Jennifer Cocohoba, PharmD
Professor
Department of Clinical Pharmacy
University of California, San Francisco
Pharmacist
Women’s HIV Program
University of California San Francisco Medical Center
San Francisco, California

Link to full program:
https://bit.ly/3PM3nYe

Follow along with the slides at:
https://bit.ly/3NpAYI1

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.